

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Donegan Michael C</u> (Last) (First) (Middle) 951 YAMATO ROAD SUITE 220 (Street) BOCA RATON FL 33431 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>TherapeuticsMD, Inc. [TXMD]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) CAO and VP of Finance
	3. Date of Earliest Transaction (Month/Day/Year) 09/29/2021	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	\$0.00	09/29/2021		A		38,954 ⁽¹⁾		(2)	(2)	Common Stock	38,954	\$0.00	38,954	D	
Non-Qualified Stock Option (right to buy)	\$5.01	09/29/2021		J ⁽³⁾		50,000 ⁽³⁾		07/09/2015 ⁽⁴⁾	07/09/2024 ⁽⁴⁾	Common Stock	50,000	\$0.00	0	D	
Non-Qualified Stock Option (right to buy)	\$8.92	09/29/2021		J ⁽³⁾		100,000 ⁽³⁾		01/17/2016 ⁽⁵⁾	12/17/2025 ⁽⁵⁾	Common Stock	100,000	\$0.00	0	D	
Non-Qualified Stock Option (right to buy)	\$6.83	09/29/2021		J ⁽³⁾		40,000 ⁽³⁾		03/15/2018 ⁽⁶⁾	03/14/2027 ⁽⁶⁾	Common Stock	40,000	\$0.00	0	D	
Non-Qualified Stock Option (right to buy)	\$5.16	09/29/2021		J ⁽³⁾		100,000 ⁽³⁾		03/15/2019 ⁽⁷⁾	03/15/2028 ⁽⁷⁾	Common Stock	100,000	\$0.00	0	D	

Explanation of Responses:

- Restricted stock units (RSUs) issued pursuant to the Issuer's stock option exchange program approved by stockholders at the Issuer's 2021 annual meeting (the "Option Exchange Program"). Each RSU represents a contingent right to receive one share of common stock of the Issuer.
- Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.
- Stock options exchanged for RSUs pursuant to the Option Exchange Program.
- Underlying shares were subject to vesting as follows: 12,500 shares on the first anniversary date of the grant, 12,500 shares on the second anniversary date of the grant, 12,500 shares on the third anniversary date of the grant, and 12,500 shares on the fourth anniversary date of the grant.
- Underlying shares were subject to vesting as follows: equal monthly installments over 12 months.
- Underlying shares were subject to vesting as follows: 13,333 shares on the first anniversary date of the grant, 13,333 shares on the second anniversary date of the grant, and 13,334 shares on the third anniversary date of the grant.
- Underlying shares were subject to vesting as follows: 33,334 shares on the first anniversary date of the grant, 33,333 shares on the second anniversary date of the grant, and 33,333 shares on the third anniversary date of the grant.

Remarks:

/s/ Michael C. Donegan 10/01/2021
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.